# Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes

> **NCT06762314** · PHASE2 · RECRUITING · sponsor: **Mostafa Bahaa** · enrollment: 105 (estimated)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Insulin
- **DRUG:** Semaglutide
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT06762314
- **Lead sponsor:** Mostafa Bahaa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2027-09-20
- **Final completion:** 2028-11-20
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762314, "Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06762314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*